Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)
Respiratory syncytial virus (RSV) is a leading cause of hospitalization in children less than 1 year of age and causes substantial morbidity. Although there is not currently a vaccine available to prevent RSV infection, prophylaxis with the humanized monoclonal antibody palivizumab has been shown to...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2007
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721348/ |